Genomic sequencing of tumor DNA has changed the therapeutic landscape for non squamous, non small cell lung cancer (NSCLC) with the discovery of recurrent oncogenic driver mutations in EGFR, ALK, and ROS‐1 that can be specifically and effectively targeted by new drugs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.